
    
      The study consists of a Treatment phase, where efficacy is determined and a Continuation
      phase for extended safety information. The Continuation phase is open to all Treatment phase
      participants and those who did not qualify for treatment because of an insufficient number of
      seizures during the Baseline phase.
    
  